Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Gilead Sciences, Inc. ("Gilead") (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or v ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Macy's CEO Tony Spring, who is trying to turn around the company, wants to prove to the public markets that its three-brand ...

Intel Capital was set up 24 years ago. It has raised $5 billion and invested in over 1,800 early-stage companies in cloud ...

Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...

Nvidia is constructing one of the largest server farms in Israel, close to the Elyakim Interchange near Yokne’am in the north ...

Just a week before he vacates the White House, President Biden signed the Interim Final Rule on Artificial Intelligence ...

Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.